Pregnancy
Conditions
Keywords
Pregnancy, Amevive, alefacept, Registry, Psoriasis
Brief summary
This is an observational, exposure-registration and follow-up study, to be conducted in the United States (US). The AMEVIVE® Pregnancy Exposure Registry is designed to monitor pregnant subjects and fetuses exposed to AMEVIVE® in order to detect any potential increase in the risk of major birth defects. The AMEVIVE® Pregnancy Exposure Registry is sponsored by Astellas Pharma Global Development and will be managed by INC Research. The Registry will be monitored by an independent Advisory Committee of external experts in relevant specialties of teratology, epidemiology, maternal and fetal medicine, and infectious disease medicine (external member details available upon request).
Detailed description
Prospective reports will be collected from pregnant subjects, health care provider (HCP), or Astellas Product Safety Management staff. Data from the pregnant subjects will be collected at 4 to 5 months of pregnancy by telephone interviews with the Registry. The Registry will also contact the subject at 2 months and 12 months after the estimated delivery date (EDD) for post-natal & pediatric follow-up. The Registry will confirm the information collected from the subject with the HCP by telephone interviews with the Registry, forms mailed/faxed to the Registry, electronic forms/queries sent to the Registry, or a combination of these methods. If a live birth is reported, the infant's HCP will be contacted for the Pediatric Follow-Up at 2 months and 12 months of age. If a birth defect is reported, targeted follow-up will be conducted.
Interventions
DRUGAmevive exposure
Observational
Sponsors
Astellas Pharma Inc
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* Have been exposed to AMEVIVE® within 8 weeks prior to conception or at any time during pregnancy * Provide sufficient information to determine that the pregnancy is prospectively registered (i.e., the outcome of pregnancy must be unknown prospectively) * Provide verbal consent to participate in the Registry, and * Verbally provide the contact information for herself, her healthcare provider (HCP), and the infant's HCP (if applicable)
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate pattern or increase in major birth defects in children of women w/ psoriasis who were exposed to AMEVIVE® at any time within the 8 wks prior to conception, or at any time during pregnancy, where outcome of the pregnancy is unknown prospectively | At month 4 to 5 of pregnancy; At 2 months and 12 months post estimated delivery date |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate gestational age, body weight, gender, head circumference, and body length in live born infants exposed to AMEVIVE® | At 2 months post estimated delivery date |
| To evaluate appearance, pulse, grimace, activity, and respiration (APGAR) scores at 1 and 5 minutes of age in live born infants exposed to AMEVIVE® | At 2 months post estimated delivery date |
| To evaluate the number of live born infants versus fetal loss in pregnant women exposed to AMEVIVE® | At 2 months post estimated delivery date |
| To evaluate clinically significant infections with unusual organisms, not requiring hospitalization in live born infants exposed to AMEVIVE® | At 2 months and 12 months post estimated delivery date |
| To evaluate malignancies in live born infants exposed to AMEVIVE® | At 2 months and 12 months post estimated delivery date |
| To evaluate hospitalizations for infection in live born infants exposed to AMEVIVE® | At 2 months and 12 months post estimated delivery date |
Countries
United States
Outcome results
None listed